

Sanja A MijatoviÄ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2159819/publications.pdf>

Version: 2024-02-01

90
papers

4,055
citations

147801

31
h-index

118850

62
g-index

95
all docs

95
docs citations

95
times ranked

6817
citing authors

#	ARTICLE	IF	CITATIONS
1	Borcalein: a Carborane-Based Analogue of Baicalein with 12-Lipoxygenase-Independent Toxicity. <i>ChemMedChem</i> , 2022, 17, .	3.2	8
2	Mesenchymal Stem Cells From Mouse Hair Follicles Reduce Hypertrophic Scarring in a Murine Wound Healing Model. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 2028-2044.	3.8	11
3	Combined Action of Hyper-Harmonized Hydroxylated Fullerene Water Complex and Hyperpolarized Light Leads to Melanoma Cell Reprogramming In Vitro. <i>Nanomaterials</i> , 2022, 12, 1331.	4.1	7
4	Carboranyl Analogues of Mefenamic Acid and Their Biological Evaluation. <i>ACS Omega</i> , 2022, 7, 24282-24291.	3.5	13
5	Carborane-Based Analog of Rev-5901 Attenuates Growth of Colon Carcinoma In Vivo. <i>Molecules</i> , 2022, 27, 4503.	3.8	3
6	The Middle Part of the Plucked Hair Follicle Outer Root Sheath Is Identified as an Area Rich in Lineage-Specific Stem Cell Markers. <i>Biomolecules</i> , 2021, 11, 154.	4.0	11
7	Arene Ruthenium(II) Complexes Bearing the \hat{I}^{P} -P or \hat{I}^{P} -S Ph ₂ P(CH ₂) ₃ SPh Ligand. <i>Molecules</i> , 2021, 26, 1860.	3.8	2
8	Antitumor potential of cisplatin loaded into SBA-15 mesoporous silica nanoparticles against B16F1 melanoma cells: in vitro and in vivo studies. <i>Journal of Inorganic Biochemistry</i> , 2021, 217, 111383.	3.5	12
9	Development of genistein-loaded gold nanoparticles and their antitumor potential against prostate cancer cell lines. <i>Materials Science and Engineering C</i> , 2021, 124, 112078.	7.3	31
10	Ruthenacarborane and Quinoline: A Promising Combination for the Treatment of Brain Tumors. <i>Molecules</i> , 2021, 26, 3801.	3.8	4
11	A Comparative Analysis of the In Vitro Anticancer Activity of Iridium(III) $\{\hat{I}^{\text{5-C5Me4R}}\}$ Complexes with Variable R Groups. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7422.	4.1	4
12	The Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors. <i>Antioxidants</i> , 2020, 9, 374.	5.1	72
13	Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. <i>Scientific Reports</i> , 2020, 10, 4827.	3.3	15
14	Quinoline-Conjugated Ruthenacarboranes: Toward Hybrid Drugs with a Dual Mode of Action. <i>ChemMedChem</i> , 2019, 14, 2061-2074.	3.2	9
15	2,2-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes. <i>ChemMedChem</i> , 2019, 14, 2075-2083.	3.2	13
16	Synthetic Tubulysin Derivative, Tubugi-1, Against Invasive Melanoma Cells: The Cell Death Triangle. <i>Anticancer Research</i> , 2019, 39, 5403-5415.	1.1	2
17	Carboranyl Analogues of Ketoprofen with Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines. <i>ACS Omega</i> , 2019, 4, 8824-8833.	3.5	11
18	The synthetic tubulysin derivative, tubugi-1, improves the innate immune response by macrophage polarization in addition to its direct cytotoxic effects in a murine melanoma model. <i>Experimental Cell Research</i> , 2019, 380, 159-170.	2.6	7

#	ARTICLE	IF	CITATIONS
19	Senescence as a main mechanism of Ritonavir and Ritonavir-NO action against melanoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 1362-1375.	2.7	18
20	The hop-derived prenylflavonoid isoxanthohumol inhibits the formation of lung metastasis in B16-F10 murine melanoma model. <i>Food and Chemical Toxicology</i> , 2019, 129, 257-268.	3.6	14
21	Impact of the mesoporous silica SBA-15 functionalization on the mode of action of Ph ₃ Sn(CH ₂) ₆ OH. <i>Materials Science and Engineering C</i> , 2019, 100, 315-322.	7.3	12
22	Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo. <i>Investigational New Drugs</i> , 2019, 37, 1014-1028.	2.6	41
23	The interaction between SBA-15 derivative loaded with Ph ₃ Sn(CH ₂) ₆ OH and human melanoma A375 cell line: uptake and stem phenotype loss. <i>Journal of Biological Inorganic Chemistry</i> , 2019, 24, 223-234.	2.6	17
24	Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines. <i>ChemMedChem</i> , 2019, 14, 315-321.	3.2	20
25	Carborane-Based Analogues of 5-Lipoxygenase Inhibitors Co-inhibit Heat Shock Protein 90 in HCT116 Cells. <i>ChemMedChem</i> , 2019, 14, 255-261.	3.2	18
26	Prostate cancer metastasis and soy isoflavones: a dogfight over a bone. <i>EXCLI Journal</i> , 2019, 18, 106-126.	0.7	4
27	Naturally occurring compounds in differentiation based therapy of cancer. <i>Biotechnology Advances</i> , 2018, 36, 1622-1632.	11.7	31
28	Delivery of [Ru(η -6-p-cymene)Cl ₂ {Ph ₂ P(CH ₂) ₃ SPh- η -P}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study. <i>Journal of Inorganic Biochemistry</i> , 2018, 180, 155-162.	3.5	14
29	Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells. <i>Molecules</i> , 2018, 23, 2463.	3.8	36
30	Drug Delivery System for Emodin Based on Mesoporous Silica SBA-15. <i>Nanomaterials</i> , 2018, 8, 322.	4.1	25
31	Aloe emodin: From antitumor action. <i>Hrana I Ishrana</i> , 2018, 59, 59-67.	0.2	2
32	Carborane-901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway. <i>ChemMedChem</i> , 2017, 12, 1081-1086.	3.2	15
33	Antiproliferative activity of (η -6-p-cymene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines. <i>Dalton Transactions</i> , 2017, 46, 12067-12080.	3.3	16
34	HIV-1 protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?. <i>International Journal of Cancer</i> , 2017, 140, 1713-1726.	5.1	63
35	Alpha-1-Antitrypsin Antagonizes Cisplatin-Induced Cytotoxicity in Prostate Cancer (PC3) and Melanoma Cancer (A375) Cell Lines. <i>Pathology and Oncology Research</i> , 2017, 23, 335-343.	1.9	4
36	Ti-SLActive and TiZr-SLActive Dental Implant Surfaces Promote Fast Osteoblast Differentiation. <i>Coatings</i> , 2017, 7, 102.	2.6	9

#	ARTICLE	IF	CITATIONS
37	(18-Crown-6)potassium(I) Trichlorido[28-acetyl-3-(tris-(hydroxymethyl)amino-ethane)betulinic ester- I^{N}]platinum(II): Synthesis and In Vitro Antitumor Activity. <i>Inorganics</i> , 2017, 5, 56.	2.7	2
38	Antiproliferative activity of ruthenium(II) arene complexes with mono- and bidentate pyridine-based ligands. <i>Dalton Transactions</i> , 2016, 45, 13114-13125.	3.3	34
39	Evaluation of functionalized mesoporous silica SBA-15 as a carrier system for $\text{Ph}_3\text{Sn}(\text{CH}_2)_3\text{OH}$ against the A2780 ovarian carcinoma cell line. <i>Dalton Transactions</i> , 2016, 45, 18984-18993.	3.3	27
40	Versatile antitumor potential of isoxanthohumol: Enhancement of paclitaxel activity in vivo. <i>Pharmacological Research</i> , 2016, 105, 62-73.	7.1	58
41	Binuclear dichlorido(C_6H_5)p-cymene)ruthenium(II) complexes with bis(nicotinate) and bis(isonicotinate) polyethylene glycol ester ligands. <i>Applied Organometallic Chemistry</i> , 2015, 29, 20-25.	3.5	8
42	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. <i>Leukemia Research</i> , 2015, 39, 1088-1095.	0.8	25
43	Improved in vitro antitumor potential of (O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV) complex under normoxic and hypoxic conditions. <i>European Journal of Pharmacology</i> , 2015, 760, 136-144.	3.5	7
44	Ruthenium(II) p-cymene complex bearing 2,2'-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 315-321.	3.5	27
45	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. <i>Oncotarget</i> , 2014, 5, 4603-4650.	1.8	231
46	A Key Role of Autophagy in Osteoblast Differentiation on Titanium-Based Dental Implants. <i>Cells Tissues Organs</i> , 2014, 200, 265-277.	2.3	37
47	Organotin(IV)-Loaded Mesoporous Silica as a Biocompatible Strategy in Cancer Treatment. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 5982-5987.	13.8	82
48	Synthesis, X-ray structure and strong in vitro cytotoxicity of novel organoruthenium complexes. <i>Journal of Organometallic Chemistry</i> , 2014, 749, 142-149.	1.8	7
49	Study of the anticancer properties of methyl- and phenyl-substituted carbon- and silicon-bridged ansa-titanocene complexes. <i>Journal of Organometallic Chemistry</i> , 2014, 751, 361-367.	1.8	10
50	Undecylprodigiosin conjugated monodisperse gold nanoparticles efficiently cause apoptosis in colon cancer cells in vitro. <i>Journal of Materials Chemistry B</i> , 2014, 2, 3271-3281.	5.8	10
51	Alkenyl-substituted titanocene dichloride complexes: Stability studies, binding and cytotoxicity. <i>Journal of Organometallic Chemistry</i> , 2014, 769, 46-57.	1.8	6
52	Anticancer Potential of (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing $\text{P}(\text{C}_6\text{H}_4)_2$ and $\text{P}(\text{C}_6\text{H}_4)_2\text{S}(\text{C}_6\text{H}_4)_2$ Coordinated $\text{Ph}_2\text{PCH}_2\text{CH}_2\text{CH}_2\text{S}(\text{O})\text{Ph}$ ($\text{X}=\text{O}$) Ligands. <i>ChemMedChem</i> , 2014, 9, 1586-1593.	3.2	10
53	Extracellular iron diminishes anticancer effects of vitamin C: An in vitro study. <i>Scientific Reports</i> , 2014, 4, 5955.	3.3	50
54	Membrane Fluidity, Invasiveness and Dynamic Phenotype of Metastatic Prostate Cancer Cells after Treatment with Soy Isoflavones. <i>Journal of Membrane Biology</i> , 2013, 246, 307-314.	2.1	22

#	ARTICLE	IF	CITATIONS
55	Apotransferrin inhibits interleukin-2 expression and protects mice from experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2013, 262, 72-78.	2.3	7
56	Biological activity of neutral and cationic iridium(III) complexes with P^{P} and $\text{P}^{\text{P}}, \text{P}^{\text{S}}$ coordinated $\text{Ph}_2\text{PCH}_2\text{S}(\text{O})\text{xPh}$ ($\text{x} = 0, 1, 2$) ligands. <i>European Journal of Medicinal Chemistry</i> , 2013, 69, 216-222.	5.5	24
57	Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2013, 259, 55-65.	2.3	9
58	No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST A^{\dagger} ELIJA NESITNO A^{\dagger} ELIJSKOG KARCINOMA PLU A^{\dagger} RAZLI A^{\dagger} CEITE OSETUIVOSTI NA DOKSORUBICIN. <i>Journal of Medical Biochemistry</i> , 2013, 32, 406-416.	1.7	2
59	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. <i>Cell Cycle</i> , 2012, 11, 1174-1182.	2.6	14
60	On the Discovery, Biological Effects, and Use of Cisplatin and Metallocenes in Anticancer Chemotherapy. <i>Bioinorganic Chemistry and Applications</i> , 2012, 2012, 1-14.	4.1	115
61	Metals in Medicine. <i>Bioinorganic Chemistry and Applications</i> , 2012, 2012, 1-2.	4.1	4
62	Melanoma tumor inhibition by tetrachlorido(O, O^{2} -dibutyl-ethylenediamine-N, N^{2} -di-3-propionate)platinum(IV) complex: in vitro and in vivo investigations. <i>Metallomics</i> , 2012, 4, 1155.	2.4	15
63	Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells. <i>Molecular Pharmacology</i> , 2012, 82, 700-710.	2.3	28
64	Platinum(II/IV) complexes containing ethylenediamine-N, N^{2} -di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells. <i>Metallomics</i> , 2012, 4, 979.	2.4	35
65	Cell-type dependent response of melanoma cells to aloe emodin. <i>Food and Chemical Toxicology</i> , 2012, 50, 3181-3189.	3.6	37
66	Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. <i>Oncology Reports</i> , 2012, 28, 682-688.	2.6	18
67	Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 1784-1795.	1.9	39
68	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. <i>Oncotarget</i> , 2012, 3, 1068-1111.	1.8	279
69	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. <i>Oncotarget</i> , 2012, 3, 954-987.	1.8	244
70	Resistance to TRAIL and how to surmount it. <i>Immunologic Research</i> , 2012, 52, 157-168.	2.9	48
71	Novel methylene modified cyclohexyl ethylenediamine-N, N^{2} -diacetate ligands and their platinum(IV) complexes. Influence on biological activity. <i>Journal of Inorganic Biochemistry</i> , 2012, 109, 40-48.	3.5	29
72	Advances in Targeting Signal Transduction Pathways. <i>Oncotarget</i> , 2012, 3, 1505-1521.	1.8	41

#	ARTICLE	IF	CITATIONS
73	In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. <i>Cell Cycle</i> , 2011, 10, 492-499.	2.6	47
74	Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. <i>Journal of Cellular Physiology</i> , 2011, 226, 1803-1812.	4.1	30
75	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. <i>Journal of Cellular Physiology</i> , 2011, 226, 2762-2781.	4.1	147
76	Multiple antimelanoma potential of dry olive leaf extract. <i>International Journal of Cancer</i> , 2011, 128, 1955-1965.	5.1	48
77	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011, 3, 192-222.	3.1	520
78	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. <i>Oncotarget</i> , 2011, 2, 135-164.	1.8	509
79	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. <i>Free Radical Biology and Medicine</i> , 2010, 48, 1090-1099.	2.9	10
80	(S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acidâ€“Nitric Oxide (GIT-27NO) â€“ New Dress for Nitric Oxide Mission. , 2010, , 443-457.		0
81	The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. <i>European Journal of Pharmacology</i> , 2009, 615, 228-233.	3.5	15
82	The antitumor properties of a nontoxic, nitric oxideâ€“modified version of saquinavir are independent of Akt. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1169-1178.	4.1	38
83	Anticancer Properties of Ganoderma Lucidum Methanol Extracts In Vitro and In Vivo. <i>Nutrition and Cancer</i> , 2009, 61, 696-707.	2.0	67
84	Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acidâ€“nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. <i>Nitric Oxide - Biology and Chemistry</i> , 2008, 19, 177-183.	2.7	26
85	Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: In vitro and in vivo study. <i>Food and Chemical Toxicology</i> , 2008, 46, 1825-1833.	3.6	63
86	Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 510-520.	4.1	68
87	Aloe emodin inhibits the cytotoxic action of tumor necrosis factor. <i>European Journal of Pharmacology</i> , 2007, 568, 248-259.	3.5	38
88	Strain difference in susceptibility to experimental autoimmune encephalomyelitis between Albino Oxford and Dark Agouti rats correlates with disparity in production of IL-17, but not nitric oxide. <i>Journal of Neuroscience Research</i> , 2006, 84, 379-388.	2.9	49
89	Anti-glioma action of aloe emodin: the role of ERK inhibition. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 589-598.	5.4	85
90	Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 1275-1282.	5.4	59